Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: A retrospective, multi-centre, international extranodal lymphoma study group study

Annals of Oncology

Volumn 24, Issue 5, 2013, Pages 1344-1351

  Wirth, A ^a   Gospodarowicz, M ^b   Aleman, B M P ^c   Bressel, M ^d   Ng, A ^e   Chao, M ^f   Hoppe, R T ^g   Thieblemont, C ^h   Tsang, R ^b   Moser, L ⁱ   Specht, L ^j   Szpytma, T ^k   Lennard, A ^l   Seymour, J F ^a   Zucca, E ^m  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Radiation Oncology Victoria   (Australia)

^g STANFORD UNIVERSITY   (United States)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j FINSEN LABORATORY   (Denmark)

^k INSTITUTE OF ONCOLOGY   (Poland)

^l FREEMAN HOSPITAL   (United Kingdom)

^m OSPEDALE SAN GIOVANNI   (Switzerland)

more..

Author keywords

Gastric lymphoma; MALT; Marginal zone; Radiotherapy

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; ERADICATION THERAPY; FEMALE; FOLLOW UP; FREEDOM FROM TREATMENT FAILURE; GASTRIC MARGINAL ZONE LYMPHOMA; GASTROSCOPY; HELICOBACTER INFECTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; RECURRENT CANCER; RETROSPECTIVE STUDY; RISK FACTOR; STOMACH LYMPHOMA; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877133143     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds623     Document Type: Article

References (51)

1. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52: 1410-1416.
2. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419-1432.
3. Stolte M, Bayerdorffer E, Morgner A et al. Helicobacter and gastric MALT lymphoma. Gut 2002; 50(Suppl 3): III19-III24.
4. Wundisch T, Thiede C, Morgner A et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 23: 8018-8024.
5. Liu H, Ye H, Ruskone-Fourmestraux A et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286-1294.
6. Sandmeier D, Benhattar J, Bouzourene H. The natural history of a gastric low grade B cell MALT lymphoma followed during 11 years without treatment. J Clin Pathol 2002; 55: 548-550.
7. de Jong D, Aleman BM, Taal BG et al. Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: an international survey. Ann Oncol 1999; 10: 275-280.
8. Gospodarowicz MK, Pintilie M, Tsang R et al. Primary gastric lymphoma: brief overview of the recent Princess Margaret Hospital experience. Recent Results Cancer Res 2000; 156: 108-115.
9. Schechter NR, Yahalom J. Low-grade MALT lymphoma of the stomach: a review of treatment options. Int J Radiat Oncol Biol Phys 2000; 46: 1093-1103.
10. Vrieling C, de Jong D, Boot H et al. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol 2008; 87: 405-411.
11. Burgers JM, Taal BG, van Heerde P et al. Treatment results of primary stage I and II non-Hodgkin's lymphoma of the stomach. Radiother Oncol 1988; 11: 319-326.
12. Koch P, del Valle F, Berdel WE et al. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19: 3874-3883.
13. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998; 16: 1916-1921.
14. Tsang RW, Gospodarowicz MK, Pintilie M et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21: 4157-4164.
15. Thieblemont C, Dumontet C, Bouafia F et al. Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. Leuk Lymphoma 2003; 44: 257-262.
16. Yahalom J, Gonzalez M, Moskowitz C et al. H. pylori independent MALT lymphoma of the stomach: 10-year experience with 51 patients treated with radiation alone. Ann Oncol 2002; 13: 42-43.
17. Nakamura S, Matsumoto T, Suekane H et al. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. Cancer 2005; 104: 532-540.
18. Rohatiner A, d'Amore F, Coiffier B et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994; 5: 397-400.
19. Lin ML, Wirth A, Chao M et al. Radiotherapy for low-grade gastric marginal zone lymphoma: a retrospective study. Intern Med J 2007; 37: 172-180.
20. Altman DG, De Stavola BL, Love SB et al. Review of survival analyses published in cancer journals. Br J Cancer 1995; 72: 511-518.
21. R-Project. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing 2012.
22. Koch P, Probst A, Berdel WE et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005; 23: 7050-7059.
23. Ferreri AJ, Montalban C. Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol 2007; 63: 65-71.
24. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?. Br J Haematol 2007; 136: 521-538.
25. El-Zahabi LM, Jamali FR, El H, II et al. The value of EUS in predicting the response of gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication. Gastrointest Endosc 2007; 65: 89-96.
26. Inagaki H, Nakamura T, Li C et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 2004; 28: 1560-1567.
27. Caletti G, Fusaroli P, Togliani T. EUS in MALT lymphoma. Gastrointest Endosc 2002; 56: S21-S26.
28. Levy M, Hammel P, Lamarque D et al. Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosaassociated lymphoid tissue treated medically. Gastrointest Endosc 1997; 46: 328-333.
29. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 2001; 48: 297-303.
30. Levy M, Copie-Bergman C, Traulle C et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol 2002; 97: 292-297.
31. de Jong D, Boot H, Taal B. Histological grading with clinical relevance in gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Recent Results Cancer Res 2000; 156: 27-32.
32. Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 2005; 16: 473-480.
33. Aviles A, Nambo MJ, Neri N et al. Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol 2005; 22: 57-62.
34. Wirth A, Teo A, Wittwer H et al. Gastric irradiation for MALT lymphoma: reducing the target volume, fast!. Australas Radiol 1999; 43: 87-90.
35. Della Biancia C, Hunt M, Furhang E et al. Radiation treatment planning techniques for lymphoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 62: 745-751.
36. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005; 23: 6415-6420.
37. Yoon SS, Coit DG, Portlock CS et al. The diminishing role of surgery in the treatment of gastric lymphoma. Ann Surg 2004; 240: 28-37.
38. Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin's lymphomas. Hematol Oncol 2005; 23: 10-17.
39. Wotherspoon AC, Doglioni C, Isaacson PG. Low-grade gastric B-cell lymphoma of mucosa-associated lymphoid tissue (MALT): a multifocal disease. Histopathology 1992; 20: 29-34.
40. El-Modir A, Glaholm J. Gastric irradiation for low-grade MALT lymphoma of the stomach: report of two cases and review of the literature. Clin Oncol (R Coll Radiol) 2002; 14: 464-467.
41. Zucca E. Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue type: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007; 18(Suppl 2): ii59-ii60.
42. Manoharan A. Sustained remissions with long-term weekly chlorambucil maintenance therapy in patients with mucosa-associated lymphoid tissue lymphoma. Int J Hematol 2004; 79: 472-473.
43. Hammel P, Haioun C, Chaumette MT et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995; 13: 2524-2529.
44. Conconi A, Martinelli G, Thieblemont C et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102: 2741-2745.
45. Martinelli G, Laszlo D, Ferreri AJ et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979-1983.
46. Zullo A, Hassan C, Andriani A et al. Treatment of low-grade gastric MALTlymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis. Med Oncol 2010; 27: 291-295.
47. Goda JS, Gospodarowicz M, Pintilie M et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 2010; 116: 3815-3824.
48. Yahalom J. Patients with H pylori-independent MALT lymphoma are curable with radiotherapy. Oncology (Williston Park) 2011; 25: 1147-1149.
49. Ruskone-Fourmestraux A, Fischbach W, Aleman BM et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011; 60: 747-758.
50. Goda JS, Le LW, Lapperriere NJ et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys 2011; 81: e659-e666.
51. Tran K, Campbell BA, Fua T et al. Low dose radiotherapy in marginal zone lymphoma: efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma. Leuk Lymphoma 2012 September 28 [epub ahead of print].